↓ Skip to main content

microRNA: Cancer

Overview of attention for book
Attention for Chapter 1: microRNA: Cancer
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
microRNA: Cancer
Chapter number 1
Book title
microRNA: Cancer
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-3-319-23730-5_1
Pubmed ID
Book ISBNs
978-3-31-923729-9, 978-3-31-923730-5
Authors

Sarver, Anne E, Li, Lihua, Kartha, Reena V, Subramanian, Subbaya, Anne E. Sarver, Lihua Li, Reena V. Kartha, Subbaya Subramanian, Sarver, Anne E., Kartha, Reena V.

Abstract

Many cancers originate as benign neoplasms that transform into malignant cancerous tumors in a multistep progression that is regulated, in part, by microRNAs. Benign neoplasms, by definition, lack the ability to invade adjacent tissues or spread to distant sites through metastasis. The benign to malignant transition is a critical intervention stage as tumors diagnosed in subsequent nonlocalized and malignant stages are exponentially more difficult to treat successfully. This chapter explores the critical roles that microRNAs play in the transformation from benign to malignant in four representative cancers: colorectal cancer, pancreatic cancer, malignant peripheral nerve sheath tumor, and prostate cancer. Understanding how these microRNAs control this progression and transformation will lead to new therapeutic targets and diagnostic biomarkers, resulting in improved treatments and patient outcomes.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 24%
Other 3 18%
Student > Bachelor 2 12%
Researcher 2 12%
Student > Ph. D. Student 1 6%
Other 3 18%
Unknown 2 12%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 24%
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Medicine and Dentistry 2 12%
Computer Science 2 12%
Nursing and Health Professions 1 6%
Other 1 6%
Unknown 5 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2016.
All research outputs
#20,320,000
of 22,862,742 outputs
Outputs from Advances in experimental medicine and biology
#3,970
of 4,951 outputs
Outputs of similar age
#296,012
of 353,295 outputs
Outputs of similar age from Advances in experimental medicine and biology
#189
of 272 outputs
Altmetric has tracked 22,862,742 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,951 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,295 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.